DGAP-News

MOLOGEN AG with poster presentation at ASCO GI 2016

DGAP-News: MOLOGEN AG / Key word(s): Conference
MOLOGEN AG with poster presentation at ASCO GI 2016

20.01.2016 / 08:03
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE N 2 / 2016 of 01/20/2016

MOLOGEN AG with poster presentation at ASCO GI 2016

Berlin, 20 January 2016 - The biotechnology company MOLOGEN AG (ISIN
DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present
data on the immunotherapy MGN1703 at the 2016 Gastrointestinal Cancers
Symposium (ASCO GI) in San Francisco, California (21 - 23 January, 2016).
The poster will outline the design of the IMPALA trial including
preliminary demographic data as well as stratification factors from the
first 200 colorectal cancer patients randomized in the study. IMPALA
started in September 2014 and is currently enrolling patients.

Abstract details:
Abstract number: TPS785
Title: "Immunomodulatory switch maintenance therapy in metastatic
colorectal carcinoma: The phase 3 IMPALA study"
Poster presentation: Trials in Progress Poster Session C: Cancers of the
Colon, Rectum, and Anus, 23 January 2016 from 7:00 a.m. to 7:55 a.m. and
12:30 p.m. to 2:00 p.m.

For more information on the 2016 Gastrointestinal Cancers Symposium (ASCO
GI) please visit the website: http://gicasym.org/ .

About IMPALA
IMPALA (Immunomodulatory MGN1703 in Patients with Advanced Colorectal
Carcinoma with tumor reduction during induction treatment) is a randomized,
international, multicenter, open-label phase III trial. Based on the
findings of the IMPACT study, IMPALA aims to prove that a switch
maintenance therapy with an active immunotherapy leads to an increased
overall survival of patients who have achieved a response during their
first line treatment of metastatic colorectal cancer in combination with or
without biologics. The primary endpoint is overall survival and secondary
study endpoints include progression-free survival, toxicity and safety, and
Quality of Life (QoL).

Approximately 540 patients from more than 100 European centers in eight
European countries, including the five major European pharma markets, will
participate in the study. IMPALA started to treat the first patients in
mid-September 2014. The study is expected to finish enrollment by the end
of 2016.

For more information on the trials IMPACT and IMPALA please visit
www.clinicaltrials.gov.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the